Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the Systemic Sclerosis Progression Investigation (SPRING) registry. Methods: Patients with SSc from the SPRING registry, meeting 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria with data on PAH onset, DU status, BOS exposure, and at least 1 year of follow-up between 2015 and 2020, and having no known PAH at baseline, were included. PAH was diagnosed with right heart catheterization during the follow-up, and its incidence rate (IR) was calculated. Kaplan-Meier curves were determined, and multivariate regression identified PAH risk factors. Results: Among 727 eligible patients with SSc, followed for a median of 2.0 years, 54 (7.4%) developed PAH (IR 3.71 per 100 patient-years [PYs]). Patients with DU who were never exposed to BOS had a higher incidence of PAH (IR 4.90 per 100 PYs) compared to those exposed to BOS, whose rates matched those without DU and who were never exposed to BOS. Risk factors independently associated with PAH development included DU (hazard ratio [HR] 1.86), age (HR 1.05), modified Rodnan skin score > 4 (HR 2.07), interstitial lung disease (HR 2.29), and acetylsalicylic acid treatment (HR 1.78). Conclusion: In our cohort, the presence of DU was confirmed as a leading risk factor for PAH development, and BOS use for DU prevention may reduce this risk. Only patients with DU who were not using BOS had an increased PAH incidence.
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry / Cacciapaglia, F; De Angelis, R; Ferri, C; Bajocchi, G; Bellando-Randone, S; Bruni, C; Orlandi, M; Fornaro, M; Cipolletta, E; Zanframundo, G; Foti, R; Cuomo, G; Ariani, A; Rosato, E; Lepri, G; Girelli, F; Zanatta, E; Bosello, Sl; Cavazzana, I; Ingegnoli, F; De Santis, M; Murdaca, G; Abignano, G; Giorgio, P; Della Rossa, A; Caminiti, M; Iuliano, A; Ciano, G; Beretta, L; Bagnato, G; Lubrano, E; De Andres, I; Giollo, A; Saracco, M; Agnes, C; Campochiaro, C; Lumetti, F; Spinella, A; Magnani, L; De Luca, G; Codullo, V; Visalli, E; Iandoli, C; Gigante, A; Pellegrino, G; Cozzi, F; Lazzaroni, Mg; Generali, E; Mennillo, G; Barsotti, S; Pagano-Mariano, G; Furini, F; Vultaggio, L; Parisi, S; Peroni, Cl; Bianchi, G; Fusaro, E; Sebastiani, Gd; Govoni, M; D'Angelo, S; Pigatto, E; Franceschini, F; Guiducci, S; Dagna, L; Doria, A; Giuggioli, D; Riccieri, V; Salvarani, C; Matucci-Cerinic, M; Iannone, F; Systemic Sclerosis Progression Investigation Group of the Italian Society for Rheumatology, (SPRING-SIR).. - In: THE JOURNAL OF RHEUMATOLOGY. - ISSN 0315-162X. - 52:2(2025), pp. 1-8. [10.3899/jrheum.2024-0750]
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry.
Ferri C;Orlandi M;Lumetti F;Spinella A;Giuggioli D;Salvarani C;
2025
Abstract
Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the Systemic Sclerosis Progression Investigation (SPRING) registry. Methods: Patients with SSc from the SPRING registry, meeting 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria with data on PAH onset, DU status, BOS exposure, and at least 1 year of follow-up between 2015 and 2020, and having no known PAH at baseline, were included. PAH was diagnosed with right heart catheterization during the follow-up, and its incidence rate (IR) was calculated. Kaplan-Meier curves were determined, and multivariate regression identified PAH risk factors. Results: Among 727 eligible patients with SSc, followed for a median of 2.0 years, 54 (7.4%) developed PAH (IR 3.71 per 100 patient-years [PYs]). Patients with DU who were never exposed to BOS had a higher incidence of PAH (IR 4.90 per 100 PYs) compared to those exposed to BOS, whose rates matched those without DU and who were never exposed to BOS. Risk factors independently associated with PAH development included DU (hazard ratio [HR] 1.86), age (HR 1.05), modified Rodnan skin score > 4 (HR 2.07), interstitial lung disease (HR 2.29), and acetylsalicylic acid treatment (HR 1.78). Conclusion: In our cohort, the presence of DU was confirmed as a leading risk factor for PAH development, and BOS use for DU prevention may reduce this risk. Only patients with DU who were not using BOS had an increased PAH incidence.File | Dimensione | Formato | |
---|---|---|---|
jrheum.2024-0750.full.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
280.12 kB
Formato
Adobe PDF
|
280.12 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris